Ostrom QT, Cioffi G, Gittleman H et al (2019) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the united States in 2012–2016. Neurooncology 21:v1–v100. https://doi.org/10.1093/neuonc/noz150

Article  Google Scholar 

For POLA, Network, Tabouret E, Nguyen AT et al (2016) Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. Acta Neuropathol 132:625–634. https://doi.org/10.1007/s00401-016-1611-8

Article  Google Scholar 

Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neurooncology 23:1231–1251. https://doi.org/10.1093/neuonc/noab106

Article  CAS  Google Scholar 

Ostrom QT, Gittleman H, Stetson L et al (2018) Epidemiology of intracranial gliomas. In: Chernov MF, Muragaki Y, Kesari S, McCutcheon IE (eds) Progress in neurological surgery. S. Karger, AG, pp 1–11

Google Scholar 

Bosma I, Vos MJ, Heimans JJ et al (2007) The course of neurocognitive functioning in high-grade glioma patients. Neurooncology 9:53–62. https://doi.org/10.1215/15228517-2006-012

Article  Google Scholar 

Meyers CA, Hess KR (2003) Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neurooncology 5:89–95. https://doi.org/10.1093/neuonc/5.2.89

Article  Google Scholar 

Giovagnoli AR, Silvani A, Colombo E, Boiardi A (2005) Facets and determinants of quality of life in patients with recurrent high grade glioma. J Neurol Neurosurg Psychiatry 76:562–568. https://doi.org/10.1136/jnnp.2004.036186

Article  CAS  PubMed  PubMed Central  Google Scholar 

Henriksson R, Asklund T, Poulsen HS (2011) Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. J Neurooncol 104:639–646. https://doi.org/10.1007/s11060-011-0565-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Klein M, Taphoorn MJ, Heimans JJ et al (2001) Neurobehavioral status and health-related quality of life in newly diagnosed high-grade glioma patients. J Clin Oncol 19:4037–4047. https://doi.org/10.1200/JCO.2001.19.20.4037

Article  CAS  PubMed  Google Scholar 

Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant Temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330

Article  CAS  PubMed  Google Scholar 

Chinot OL, Wick W, Mason W et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–722. https://doi.org/10.1056/NEJMoa1308345

Article  CAS  PubMed  Google Scholar 

Gilbert MR, Dignam JJ, Armstrong TS et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708. https://doi.org/10.1056/NEJMoa1308573

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stupp R, Hegi ME, Gorlia T et al (2014) Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071 – 22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 15:1100–1108. https://doi.org/10.1016/S1470-2045(14)70379-1

Article  CAS  PubMed  Google Scholar 

van den Bent M, Gan HK, Lassman AB et al (2017) Efficacy of Depatuxizumab Mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study. Cancer Chemother Pharmacol 80:1209–1217. https://doi.org/10.1007/s00280-017-3451-1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weller M, Butowski N, Tran DD et al (2017) Rindopepimut with Temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol 18:1373–1385. https://doi.org/10.1016/S1470-2045(17)30517-X

Article  CAS  PubMed  Google Scholar 

Stupp R, Taillibert S, Kanner A et al (2017) Effect of Tumor-Treating fields plus maintenance Temozolomide vs maintenance Temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial. JAMA 318:2306–2316. https://doi.org/10.1001/jama.2017.18718

Article  CAS  PubMed  PubMed Central  Google Scholar 

Friedman HS, Petros WP, Friedman AH et al (1999) Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17:1516–1525

CAS  PubMed  Google Scholar 

Jeremic B, Grujicic D, Jevremovic S et al (1992) Carboplatin and Etoposide chemotherapy regimen for recurrent malignant glioma: a phase II study. J Clin Oncol 10:1074–1077

CAS  PubMed  Google Scholar 

Wick W, Gorlia T, Bendszus M et al (2017) Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med 377:1954–1963. https://doi.org/10.1056/NEJMoa1707358

Article  CAS  PubMed  Google Scholar 

Reardon DA, Brandes AA, Omuro A et al (2020) Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the checkmate 143 phase 3 randomized clinical trial. JAMA Oncol 6:1003–1010. https://doi.org/10.1001/jamaoncol.2020.1024

Article  PubMed  Google Scholar 

Kole AJ, Park HS, Yeboa DN et al (2016) Concurrent chemoradiotherapy versus radiotherapy alone for biopsy-only glioblastoma multiforme: CRT versus RT for Biopsy-Only GB. Cancer 122:2364–2370. https://doi.org/10.1002/cncr.30063

Article  CAS  PubMed  Google Scholar 

Harlay V, Appay R, Bequet C et al (2023) Radio-chemotherapy feasibility for biopsy-only unresectable IDH wild-type glioblastomas (BO-GB). Neuro-Oncology Pract 10:536–543. https://doi.org/10.1093/nop/npad028

Article  Google Scholar 

Wen PY, Chang SM, Van den Bent MJ et al (2017) Response assessment in Neuro-Oncology clinical trials. JCO 35:2439–2449. https://doi.org/10.1200/JCO.2017.72.7511

Article  CAS  Google Scholar 

Houillier C, Wang X, Kaloshi G et al (2010) IDH1 or IDH2 mutations predict longer survival and response to Temozolomide in low-grade gliomas. Neurology 75:1560–1566. https://doi.org/10.1212/WNL.0b013e3181f96282

Article  CAS  PubMed  Google Scholar 

Quillien V, Vauléon É, Saikali S et al (2011) Intérêt de La MGMT Dans les gliomes. Bull Cancer 98:291–303. https://doi.org/10.1684/bdc.2011.1332

Article  CAS  PubMed  Google Scholar 

Barrié M, Couprie C, Dufour H et al (2005) Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme. Ann Oncol 16:1177–1184. https://doi.org/10.1093/annonc/mdi225

Article  PubMed  Google Scholar 

Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972. https://doi.org/10.1200/JCO.2009.26.3541

Article  PubMed  Google Scholar 

Löber-Handwerker R, Döring K, Bock C et al (2022) Defining the impact of adjuvant treatment on the prognosis of patients with inoperable glioblastoma undergoing biopsy only: does the survival benefit outweigh the treatment effort? Neurosurg Rev 45:2339–2347. https://doi.org/10.1007/s10143-022-01754-y

Article  PubMed  PubMed Central  Google Scholar 

Galvin A, Soubeyran P, Brain E et al (2024) Assessing patient-reported outcomes (PROs) and patient-related outcomes in randomized cancer clinical trials for older adults: results of DATECAN-ELDERLY initiative. J Geriatric Oncol 15:101611. https://doi.org/10.1016/j.jgo.2023.101611

Article  CAS  Google Scholar 

Salvador M-G, Marcela R-F, Joel R-S, Robert A (2017) Patient empowerment in neuro-oncology: new perspectives on an emerging concept. Insights Neurooncol 1. https://doi.org/10.36959/828/330

McCorkle R, Ercolano E, Lazenby M et al (2011) Self-management: enabling and empowering patients living with cancer as a chronic illness. Cancer J Clin 61:50–62. https://doi.org/10.3322/caac.20093

Article  Google Scholar 

Bottomley A, Vanvoorden V, Flechtner H, Therasse P (2003) The challenges and achievements involved in implementing quality of life research in cancer clinical trials. Eur J Cancer 39:275–285. https://doi.org/10.1016/S0959-8049(02)00729-3